Empagliflozin Modify gut microbiota in db/db Mice Correlating with the Improvement of Glucose and Lipid Metabolism

Abstract excerpt

<h4>Background: </h4> Empagliflozin (EMPA) is a widely used medication in the treatment of Type 2 diabetes Mellitus (T2DM). It functions by inhibiting glucose reabsorption by the kidneys, which helps lower blood glucose levels. Studies have shown that there is a bidirectional relationship between oral medications and the gut microbiota. The gut microbiota is one of the most complex and diverse microbial communitie...

Topics

Open a Topic to create a Post that cites this publication.

• Clostridium difficile and Clostridium perfringens research
• Diet and metabolism studies
• Diet, Metabolism, and Disease
• Drug Transport and Resistance Mechanisms
• Gastrointestinal motility and disorders
• Ginseng Biological Effects and Applications
• Gut microbiota and health
• Nutritional Studies and Diet

Identifiers and source

Literature Corpus work

9f7c9246-9e72-5901-bc1a-ffede3f3e53d

DOI

10.21203/rs.3.rs-3034344/v1